약물유전체학 시장은 2024-2031년의 CAGR이 8.9%로, 2030년까지는 195억 달러에 달할 것으로 예측되고 있습니다.
광범위한 1차 조사와 2차 조사, 시장 시나리오의 상세 분석에 의해 주요 업계 촉진요인, 억제요인, 과제, 기회를 조사하고 있습니다. 약물유전체학 시장의 성장의 배경에는 약물유전체학 바이오마커의 치료 용도의 확대, 맞춤형 의약품의 채택 확대, 고령자 인구의 증가와 만성질환의 유행, 미국 FDA와 EMA에 의한 Drug Discovery·개발에서 약물유전체학 데이터의 사용 권장 등이 있습니다. 그러나 맞춤형 의약품의 고비용이 이 시장의 성장을 억제하고 있습니다.
또한 신경질환 및 암 치료에서 약물유전체학의 응용 확대, 정도를 향상시킨 새로운 첨단 진단 툴의 개발, 약물유해반응에 관한 의식의 향상은 약물유전체학 시장에서 활동하는 기업에게 성장 기회를 가져올 것으로 기대되고 있습니다. 그러나 약물유전체학과 맞춤형 의료에 대한 낮은 인지도, 유전자 검사와 그 이점에 대한 이해의 부족, 유전자 검사와 정밀의료에 대한 상환의 부족은 시장 성장에 영향을 미치는 큰 과제입니다.
(주 : 상위 5사의 SWOT 분석 게재 예정)
The pharmacogenomics market is expected to reach $19.5 billion by 2030, at a CAGR of 8.9% from 2024 to 2031.
With extensive primary and secondary research and in-depth analysis of the market scenario, the report studies the key industry drivers, restraints, challenges, and opportunities. The growth of the pharmacogenomics market is attributed to the growing therapeutic applications of pharmacogenomic biomarkers, the increasing adoption of personalized medicines, the rising geriatric population and chronic disease prevalence, and the U.S. FDA's and EMA's recommendations for using pharmacogenomic data in drug discovery & development. However, the high costs of personalized medicines restrain the growth of this market.
Furthermore, the increasing application of pharmacogenomics in the treatment of neurological disorders and cancers, the development of new, more advanced diagnostic tools with improved accuracy, and growing awareness regarding adverse drug reactions are expected to generate growth opportunities for the players operating in the pharmacogenomics market. However, low awareness about pharmacogenomics and personalized medicine, the limited understanding of genetic testing and its benefits, and the lack of reimbursements for genetic testing and precision medicine are major challenges impacting market growth.
Based on offering, the global pharmacogenomics market is segmented into consumables, instruments, and software & services. In 2024, the consumables segment is expected to account for the largest share of the market. The largest market share of this segment is attributed to the recurrent use of consumables over instruments and the high burden of chronic diseases. Moreover, the high increasing prevalence of chronic diseases coupled with the focus of players for the launch of advanced and better reagents & kits drives the segment growth.
Based on technology, the global pharmacogenomics market is segmented into polymerase chain reaction (PCR), sequencing, microarray, mass spectrometry, electrophoresis, and other technologies. In 2024, the polymerase chain reaction (PCR) segment is expected to account for the largest share of the pharmacogenomics market. The large market share of this segment is attributed to the high sensitivity, accuracy, low sample volume requirements, and cost-effectiveness coupled with the high presence of PCR base across all the end users, initiatives by players to launch and get approvals for new PCR products for pharmacogenomics, and a wide range of applications of the PCR.
Based on application, the global pharmacogenomics market is segmented into oncology, mental health cardiology, neurological disorders, infectious diseases, and other applications. The oncology segment is expected to register the fastest CAGR during the forecast period of 2024-2031. The fast growth of this segment is attributed to the increasing prevalence of cancer cases and the need for targeted cancer treatment, growing demand for precision oncology, and growing research activities for precision oncology.
Based on end user, the global pharmacogenomics market is segmented into hospitals & diagnostic laboratories, academic and research institutes, and other end users. In 2024, the hospitals & diagnostic laboratories segment is expected to account for the largest share of the global pharmacogenomics Market. The large market share of this segment is attributed to the growing adoption of precision medicine, the growing prevalence of chronic diseases, the large number of clinical trials conducted at hospitals and diagnostic laboratories, and the focus of pharmacogenomic testing services companies on acquisitions and launches of pharmacogenomic testing services. For instance, in 2023, Incite Health Pty Limited (Australia), a pharmacogenomic testing company, acquired CNSDose LLC (U.S.), a pharmacogenomic test provider.
An in-depth analysis of the geographical scenario of the pharmacogenomics market provides detailed qualitative and quantitative insights into five major geographies: North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa, along with the coverage of major countries in each region. Asia-Pacific is slated to register the highest CAGR during the forecast period. Rising government spending to increase testing capacities; increasing cases of inherited diseases such as Down Syndrome, cystic fibrosis, sickle cell disease, colon (colorectal) cancer, and breast cancer; growing awareness about the significance of genetic tests; and increasing government initiatives promoting genetic testing contribute to the growth of the market.
Some of the key players operating in the global pharmacogenomics market are F. Hoffmann-La Roche AG (Switzerland), Abbott Laboratories (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Agilent Technologies, Inc. (U.S.), Illumina, Inc. (U.S.), PerkinElmer, Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Danaher Corporation (U.S.), QIAGEN N.V. (Netherlands), and Pacific Biosciences of California, Inc. (U.S.).
Pharmacogenomics Market, by Offering
Pharmacogenomics Market, by Technology
(Note: Other Technologies include nucleic acid amplification technology and in situ hybridization)
Pharmacogenomics Market, by Application
(Note: Other Applications include pain management, adverse drug reactions, autoimmune diseases, metabolic disorders, pulmonary diseases, hematology, dermatology, transplantation, urology, analgesia, anesthesiology, antidotal therapy, and forensic pathology)
Pharmacogenomics Market, by End User
(Other End Users include pharmaceutical & biotechnology companies, clinical research organizations (CROS), and forensic laboratories)
Pharmacogenomics Market, by Geography
(Note: SWOT Analysis of Top 5 Companies Will Be Provided)